COO
The Cooper Companies, Inc.
COO has the edge over NVO overall, supported by stronger valuation and lower modeled downside.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
COO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
COO's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
COO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $62.19 | — |
| Cheap | 17x | $50.37 | -19% |
| Current | 21x | $62.19 | — |
| Fair | 40x | $117 | +89% |
| Expensive | 61x | $179 | +189% |
Historical ranges are pointers, not guarantees.
COO's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over COO in the historical PE scenario, which offers more potential upside but is not a forecast.
COO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect COO's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
COO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.64 | +59% |
| Q3 2026 | $2.92 | +43% |
| Q2 2026 | $1.17 | -43% |
| Q1 2026 | $2.01 | -2.9% |
| Q4 2025 | $1.87 | -4.6% |
| Q3 2025 | $2.04 | +14% |
| Q2 2025 | $2.07 | +22% |
| Q1 2025 | $2.07 | +42% |
| Q4 2024 | $1.96 | +32% |
COO's earnings per share have fallen from their peak: $2.92 over the past year, against $14.79 in late 2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
COO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +0.6% |
| Q2 2026 | $1.1B | +7.9% |
| Q1 2026 | $1B | +6.2% |
| Q4 2025 | $1.1B | +4.6% |
| Q3 2025 | $1.1B | +5.7% |
| Q2 2025 | $1B | +6.3% |
| Q1 2025 | $964.7M | +3.6% |
| Q4 2024 | $1B | +9.8% |
COO's revenue has grown year over year for 23 quarters in a row: $1.1B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +4.3 points |
| Q2 2026 | -2.9% | -21 points |
| Q1 2026 | 21% | +1.9 points |
| Q4 2025 | 13% | -6.3 points |
| Q3 2025 | 17% | -2.6 points |
| Q2 2025 | 18% | +1.3 points |
| Q1 2025 | 19% | +2.4 points |
| Q4 2024 | 19% | +4.8 points |
COO's operating margin was 21% last quarter, up 4.3 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over COO on profitability, with a higher operating margin.
COO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $273M | +66% |
| Q2 2026 | $96.4M | +433% |
| Q1 2026 | $158.7M | +57% |
| Q4 2025 | $149.9M | +17% |
| Q3 2025 | $164.5M | +39% |
| Q2 2025 | $18.1M | -51% |
| Q1 2025 | $101.2M | +2100% |
| Q4 2024 | $128.1M | +339% |
COO has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
COO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -1.6M shares |
| 1 year | -3.3% | -6.6M shares |
| 3 years | -3.1% | -6.2M shares |
| 5 years | -2.9% | -5.8M shares |
| Available history | -3.3% | -6.6M shares |
COO has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $339.2M |
| Q2 2026 | $15.5M |
| Q1 2026 | $92.5M |
| Q4 2025 | $196.8M |
| Q3 2025 | $52.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
COO spent $644M buying back its own shares over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
COO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.2x | Moderate |
| Q4 2024 | 2.3x | Moderate |
COO's net debt is about 2.6 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over COO on leverage, with a lower net debt burden relative to earnings.
COO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.3 | Neutral |
| Stochastic | 38.2 | Neutral |
COO's weekly RSI is 46 (neutral) and its Stochastic is 38 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
COO PE vs Healthcare Sector
| Metric | COO | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 22 | 29 | 7 pts below |
COO is trading at 21x earnings, a 18% discount to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over COO on valuation relative to its sector.
COO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $58.7 | 5.9% above |
| 20 week MA | $65.3 | 4.7% below |
| 50 week MA | $70.3 | 12% below |
| 100 week MA | $74.3 | 16% below |
| 200 week MA | $83.9 | 26% below |
COO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 26% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
COO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.3 | $89.6 | +12% |
| 2021 | $89.6 | $102.8 | +15% |
| 2022 | $102.8 | $83.2 | -19% |
| 2023 | $83.2 | $94.6 | +14% |
| 2024 | $94.6 | $92.3 | -2.4% |
| 2025 | $92.3 | $82.6 | -11% |
| 2026 YTD | $82.6 | $62.2 | -25% |
COO has finished lower in three of the last six years. It's down 25% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over COO on returns for 2026, with the stronger performance.